Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Across 20 different cancers, tumor-agnostic approvals wove their way into several NCCN guideline updates published throughout 2024; this included the additions of repotrectinib (Augtyro) for patients 12 years or older with solid tumors that have an NTRK …